In the study, 34 healthy sedentary male volunteers were randomly divided into two groups as NM (n = 17) and SHAM-NM (n = 17). After the initial evaluation of the individuals, femoral nerve NM and placebo NM techniques were administered three sets a day with ten repetitions for three days a week for three weeks. Three days after the end of the applications, the second evaluations were made and the DOMS creation protocol for the quadriceps femoris (QF) muscle was initiated. In order to trigger DOMS in individuals, 30 sets and 10 repetitions of eccentric knee extension (35°-95° flexion angles, 30°/sec speed) were performed on the dominant lower extremity with an isokinetic dynamometer. Baseline evaluations were repeated immediately after the DOMS protocol, and at hours 24, 48, and 72. During evaluations, muscle damage (serum creatine kinase (CK), lactate dehydrogenase (LDH), and inflammation (interleukin-6 (IL-6), tumor necrosis factor-alpha) biomarkers, pain (activity), pressure pain threshold, and performance (one-leg jump, vertical jump) parameters were measured.
Age range
18 Years – 32 Years
Sex
MALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Change from Baseline Muscle Soreness at 4 weeks
Timeframe: up to 4 weeks
Change from Baseline Muscle damage marker (Creatine kinase (U/L)) at 4 weeks
Timeframe: up to 4 weeks
Change from Baseline Muscle damage marker (Laktat dehidrogenaz (U/L)) at 4 weeks
Timeframe: up to 4 weeks
Change from Baseline Inflammatory stress marker (Tumor necrosis factor-alfa ((pg/ml)) at 4 weeks
Timeframe: up to 4 weeks
Change from Baseline Inflammatory stress marker (Human interleukin-6 (pg/ml)) at 4 weeks
Timeframe: up to 4 weeks
Change from Baseline Pressure Pain Threshold (N/cm2) at 4 weeks
Timeframe: up to 4 weeks
Change from Baseline One leg hop test (cm) at 4 weeks
Timeframe: up to 4 weeks